NL
DE
Professor of Clinical Pharmacy David Burger, affiliated with the Radboudumc Pharmacy, is in the list of top scientists in the field of anti-HIV medication.
1 December is World AIDS Day. In this context, the website www.expertscape.com has announced the top scientists who have published the most scientific articles in the field of anti-HIV medication since 2011.
David Burger, professor of clinical pharmacy and affiliated with the Pharmacy of the Radboudumc, is among the top 0.1% with a 16th position on this list (out of a total of 50,000 scientists).
For more information, click here.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
The European Hector Research Award in HIV 2021 awarded to Angela Colbers and David Burger
2 November 2021 On Friday 29 October 2021, during the 18th European AIDS Conference in London, the Hector Research Award for the best scientific article related to clinical or epidemiological HIV research was presented to Angela Colbers and David Burger, both working in the Pharmacy of the RadboudUMC. read more
Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis
25 January 2021Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.
read more
Radboudumc research leads to simplified dose of HIV medication for children
31 August 2020 For children living with HIV, an adapted, simpler combination therapy is now available. Thanks to research by the Radboudumc, it is now clear that the use of one easily available tablet of dolutegravir in children gives just as good treatment results as a combination of several. read more
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2)
12 May 2020 In Lancet HIV RIHS researchers Angela Colbers and David Burger showed in an open-label, randomized controlled trial, that, when initiated in the 3rd trimester of pregnancy, achievement of VL <50cp/mL at delivery was more likely with dolutegravir-based therapy than with efavirenz-based regimens. read more
The effect of pregnancy on the pharmacokinetics of dolutegravir in women living with HIV
17 March 2020 In Clinical infectious diseases RIHS researchers Pauline Bollen, Jolien Freriksen, Angela Colbers and David Burger together with researchers of the PANNA network showed that dolutegravir use in pregnancy results in effective plasma concentrations. read more
